Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 3, 2010, Pages 410-411

  Agostinis, F ^a   Forti, S ^b   Di Berardino, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

Grass pollen; Immunotherapy; Rhinitis; Rhinoconjunctivitis; Transcutaneous

Indexed keywords

ANTIHISTAMINIC AGENT; GRASS POLLEN EXTRACT;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINOCONJUNCTIVITIS; SYMPTOM; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; CHILD; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PLANT EXTRACTS; POACEAE; RHINITIS, ALLERGIC, SEASONAL; SKIN TESTS;

EID: 76249109477     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2009.02189.x     Document Type: Article

References (4)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998 102 : 558 562.
2. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005 60 : 4 12.
3. Ghoreishi M, Dutz JP. Tolerance induction by transcutaneous immunization through ultraviolet-irradiated skin is transferable through CD4+ CD25+ T regulatory cells and is dependent on host-derived IL-10. J Immunol 2006 176 : 2635 2644.
4. Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP) : Concept Paper on the preparation of a guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. In: 18504/2006: EMEA/CHMP/EWP; 2006.